"X-linked Nuclear Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
ATP-dependent DNA helicase that contains two N-terminal ZINC FINGERS and C-terminal ATP-binding and helicase domains. It functions in the regulation of gene transcription and CHROMATIN REMODELING. ATRX undergoes cell-cycle dependent phosphorylation, which causes it to translocate from the NUCLEAR MATRIX to CHROMATIN; thus, it may change its role from gene regulation during INTERPHASE to ensuring proper chromosome segregation at MITOSIS. Mutations in the ATRX gene are associated with cases of X-LINKED MENTAL RETARDATION co-morbid with ALPHA-THALASSEMIA (ATRX syndrome).
| Descriptor ID |
D000075924
|
| MeSH Number(s) |
D08.811.399.340.375
|
| Concept/Terms |
X-linked Nuclear Protein- X-linked Nuclear Protein
- Nuclear Protein, X-linked
- X linked Nuclear Protein
- RAD54 Homolog Protein
- Homolog Protein, RAD54
- ATRX Protein
|
Below are MeSH descriptors whose meaning is more general than "X-linked Nuclear Protein".
Below are MeSH descriptors whose meaning is more specific than "X-linked Nuclear Protein".
This graph shows the total number of publications written about "X-linked Nuclear Protein" by people in this website by year, and whether "X-linked Nuclear Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 3 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "X-linked Nuclear Protein" by people in Profiles.
-
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024 Aug 08; 15(1):6775.
-
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas. Nat Commun. 2024 Jan 25; 15(1):730.
-
Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma. Neuro Oncol. 2024 01 05; 26(1):55-67.
-
Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. Dis Model Mech. 2022 08 01; 15(8).
-
ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022 01 11; 38(2):110216.
-
Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci Adv. 2020 08; 6(32):eaba8415.
-
Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020 06 15; 80(12):2663-2675.
-
Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype. Acta Neuropathol Commun. 2019 05 16; 7(1):76.
-
ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. Clin Neuropathol. 2019 Mar/Apr; 38(2):59-73.
-
G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nat Commun. 2019 02 26; 10(1):943.